Ozempicthe treatment against diabetes that reached the fame converted into medication for weight loss has lived for a convulsive years that could have resulted in a “death for success.” The popularity of the drug created a severe supply problem. Now, the World Health Organization (WHO) has taken a new step to improve access to the drug, especially in less favored countries.
Updating the list. The (WHO) has up to date its model list of essential medicines (EML). The new list Includes GLP-1 drugswhich emulate the peptide that gives its name to the group, the family of treatments flagging by Ozempic. According to the international organism, this inclusion aims to improve access to the popular drug, especially in countries with less income.
The extension covers other drugs, such as treatments against various types of cancer, against cystic fibrosis, psoriasis, hemophilia and other blood -related disorders.
In total, the new list now incorporates 523 essential medicines. The extension It also affects the WHO model list of essential pediatric medicines (EMLC), which now has 374 treatments.
The “GLP-1 family”. The incorporation of the GLP-1 drugs includes compounds such as semaglutida (the Ozempic base and Wegovy), the dorara and the liraglutid Zepbound and Mounjaro). These types of compounds act as agonists of the hormone receptors that we know as LPG-1, or Peptide similar to type-1 glucagon (although some also work as agonists of other hormones).
This hormone is produced and segregated by our body after meals and meets Two key functions. On the one hand, it informs the pancreas of the intake to reinforce insulin production, hence these compounds help people with diabetes.
The second function of this peptide is the one that makes these useful drugs to lose weight. The LPG-1 also transmits information to our brain, information that it interprets as the feeling of satiety.
Improve access. According to WHO explains in a press releasethese drugs can help people with type 2 diabetes improve their glycemic control, but they are also able to “reduce the risk of cardiovascular and renal complications, favor weight loss and even reduce the risk of premature death, especially if they have renal or cardiac failure ”, a fact that would be based, at least in part, the decision.
As details in the international organism, the price of these drugs implies significant access to them. Its inclusion in the list aims to expand this access, prioritizing patients who can benefit the most while fostering competition through genericians capable of bringing these medications to primary care, “especially in unattended areas.”
“A large part of the direct spending of families in noncommunicable diseases is destined for medicines (…). To offer equitable access to essential medicines, an equal response of health systems, a strong political will, multisectoral cooperation and programs focused on people who allow everyone,” detailed in the press release Deusdedit Mumbangizi, Director of Policies and Standards for Medicines and Health Products of the WHO.
Expanding in the fight against cancer. The expansion of WHO lists also include several cancer treatments, including several antineoplastic, drugs that seek to avoid the formation of growth that can become cancerous or neoplasms. Among these drugs are inhibitors of the immune control point PD-1/PD-L1, which help our immune system To recognize and attack with cancer cells.
In Xataka | China is the great candy of pharmaceutical thinning. And there is a wild race for selling the new ozempic
Image | Chemist4u / Yann Forget
GIPHY App Key not set. Please check settings